Kazuhiko Yanai spends much of his time researching Pathology, Histamine, Histamine H1 receptor, Internal medicine and Endocrinology. His research on Pathology frequently connects to adjacent areas such as Positron emission tomography. His research in Histamine is mostly focused on Histaminergic.
The concepts of his Histaminergic study are interwoven with issues in Orexin, Histamine H3 receptor, Histamine receptor, Neuroscience and Convulsion. His Histamine H1 receptor research includes elements of Doxepin, Anesthesia, Pharmacology, Antihistamine and Human brain. When carried out as part of a general Internal medicine research project, his work on Neuropeptide, Hypothalamus, Neurotransmitter and Dopamine receptor D3 is frequently linked to work in Leptin, therefore connecting diverse disciplines of study.
Kazuhiko Yanai focuses on Histamine, Internal medicine, Pharmacology, Histamine H1 receptor and Endocrinology. His Histamine research integrates issues from Receptor, Histidine decarboxylase, Histamine H3 receptor and Histamine H2 receptor. His Pharmacology study focuses on Antihistamine in particular.
He has researched Histamine H1 receptor in several fields, including Histamine receptor, Doxepin, Human brain and Positron emission tomography. His Positron emission tomography research is multidisciplinary, relying on both Alzheimer's disease, Dementia and Nuclear magnetic resonance. Kazuhiko Yanai studies Endocrinology, namely Hippocampus.
Kazuhiko Yanai mainly focuses on Pathology, Histamine, Internal medicine, Positron emission tomography and Pharmacology. Specifically, his work in Histamine is concerned with the study of Histaminergic. His biological study spans a wide range of topics, including Fluorodeoxyglucose and Endocrinology.
His work deals with themes such as Heparan sulfate and Histamine H3 receptor, which intersect with Endocrinology. Kazuhiko Yanai interconnects Alzheimer's disease, Magnetic resonance imaging and Amyloid in the investigation of issues within Positron emission tomography. As a part of the same scientific family, he mostly works in the field of Pharmacology, focusing on Histamine H1 receptor and, on occasion, Histamine receptor, Antihistamine, Doxepin, Sedative and Cell biology.
His primary scientific interests are in Pathology, Alzheimer's disease, Positron emission tomography, Dementia and Nuclear medicine. His study in the fields of Amyloid under the domain of Pathology overlaps with other disciplines such as Germline mutation. His work on Tau protein as part of general Alzheimer's disease study is frequently linked to Biological property, bridging the gap between disciplines.
His study in Positron emission tomography is interdisciplinary in nature, drawing from both Frontal lobe, Neuroimaging and Enantiomer. Dementia is a subfield of Internal medicine that he explores. His research investigates the connection between Structure–activity relationship and topics such as Pharmacology that intersect with issues in Anesthesia.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Psychosis pathways converge via D2high dopamine receptors.
Philip Seeman;Johannes Schwarz;Jiang Fan Chen;Henry Szechtman.
Specific brain processing of facial expressions in people with alexithymia: an H215O‐PET study
Michiko Kano;Shin Fukudo;Jiro Gyoba;Miyuki Kamachi.
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease
Michelle T Fodero-Tavoletti;Nobuyuki Okamura;Shozo Furumoto;Rachel S Mulligan.
Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors
Isao Inoue;Kazuhiko Yanai;Daisuke Kitamura;Ichiro Taniuchi.
Proceedings of the National Academy of Sciences of the United States of America (1996)
2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients
Yukitsuka Kudo;Nobuyuki Okamura;Shozo Furumoto;Manabu Tashiro.
The Journal of Nuclear Medicine (2007)
Behavioral Characterization of Mice Lacking Histamine H3 Receptors
Hiroshi Toyota;Christine Dugovic;Muriel Koehl;Aaron D. Laposky.
Molecular Pharmacology (2002)
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.
Ryuichi Harada;Nobuyuki Okamura;Shozo Furumoto;Katsutoshi Furukawa.
The Journal of Nuclear Medicine (2016)
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.
Nobuyuki Okamura;Shozo Furumoto;Ryuichi Harada;Tetsuro Tago.
The Journal of Nuclear Medicine (2013)
Consensus group on new‐generation antihistamines (CONGA): present status and recommendations
S. T. Holgate;G. W. Canonica;F. E. R. Simons;M. Taglialatela.
Clinical & Experimental Allergy (2003)
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
Nobuyuki Okamura;Shozo Furumoto;Michelle T. Fodero-Tavoletti;Rachel S. Mulligan.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: